Postoperative Pain After Caesarian Section

Sponsor
Conrad Arnfinn Bjørshol (Other)
Overall Status
Completed
CT.gov ID
NCT05659823
Collaborator
(none)
108
1
3
12.1
8.9

Study Details

Study Description

Brief Summary

To examine if perioperative pain/nausea/pruritus is altered when current standard analgesia for caesarian section (CS) is replaced with new guideline recommended analgesia.

Condition or Disease Intervention/Treatment Phase
  • Drug: Bupivacaine-fentanyl-morphine elective group
  • Drug: Bupivacaine-fentanyl elective group
  • Drug: Bupivacaine-fentanyl emergency group
Phase 4

Detailed Description

Control group (current analgesia, elective CS) is compared to current analgesia for emergency CS, and guideline recommended analgesia.

Current analgesia for CS:
Spinal hyperbaric bupivacaine 5 mg/ml, 9-11 mg. Spinal fentanyl 10-15 ug. Postoperative:

Paracetamol 1g x 4, ibuprofen 400 mg x 4 po, oxycodone 10 mg (<70 kg) or 20 mg (>70 kg) x 2 po, additional oxycodone 2,5 mg iv/5 mg po when needed.

Guideline recommended analgesia for CS:

Spinal hyperbaric bupivacaine 5 mg/ml, 9-11 mg. Spinal fentanyl 12,5 ug. Spinal morphine 0,05 mg. After delivery of baby: Dexamethasone 8 mg iv, paracetamol 1g iv, parecoxib 40 mg iv.

Postoperative: Paracetamol 1g x 4, ibuprofen 600 mg x 4 po, oxycodone 2,5 mg iv/5 mg po when needed.

Study Design

Study Type:
Interventional
Actual Enrollment :
108 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Current treatment: Patients receive elective or emergency CS. Guideline recommended treatment: Only elective CS included.Current treatment: Patients receive elective or emergency CS. Guideline recommended treatment: Only elective CS included.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Impact of Guideline Recommendations for Post-caesarean Analgesia on Pain, Nausea and Pruritus
Actual Study Start Date :
Nov 2, 2020
Actual Primary Completion Date :
Nov 5, 2021
Actual Study Completion Date :
Nov 5, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Control group

Elective CS patients receiving current analgesia.

Drug: Bupivacaine-fentanyl elective group
Current analgesia in elective caesarian section.

Experimental: Intervention group

Elective CS patients receiving guideline recommended analgesia.

Drug: Bupivacaine-fentanyl-morphine elective group
Guideline recommended analgesia in elective caesarian section.

Experimental: Emergency group

Emergency CS receiving current analgesia.

Drug: Bupivacaine-fentanyl emergency group
Current analgesia in emergency caesarian section.

Outcome Measures

Primary Outcome Measures

  1. Postoperative pain at postoperative care unit arrival [Immediately upon arrival at postoperative care unit]

    Postoperative pain during rest and movement measured by numeric rating scale (NRS).

  2. Postoperative pain at 30 minutes [At postoperative care unit 30 minutes after arrival]

    Postoperative pain during rest and movement measured by numeric rating scale (NRS).

  3. Postoperative pain at 60 minutes [At postoperative care unit 60 minutes after arrival]

    Postoperative pain during rest and movement measured by numeric rating scale (NRS).

  4. Postoperative pain at 90 minutes [At postoperative care unit 90 minutes after arrival]

    Postoperative pain during rest and movement measured by numeric rating scale (NRS).

  5. Postoperative pain at 120 minutes [At postoperative care unit 120 minutes after arrival]

    Postoperative pain during rest and movement measured by numeric rating scale (NRS).

  6. Postoperative pain at maternity ward arrival [Immediately upon arrival at maternity ward]

    Postoperative pain during rest and movement measured by numeric rating scale (NRS).

  7. Postoperative pain at maternity ward 4 hours after arrival [At maternity ward 4 hours after arrival]

    Postoperative pain during rest and movement measured by numeric rating scale (NRS).

  8. Postoperative pain at maternity ward 8 hours after arrival [At maternity ward 8 hours after arrival]

    Postoperative pain during rest and movement measured by numeric rating scale (NRS).

  9. Postoperative pain at maternity ward 12 hours after arrival [At maternity ward 12 hours after arrival]

    Postoperative pain during rest and movement measured by numeric rating scale (NRS).

  10. Postoperative pain at maternity ward 16 hours after arrival [At maternity ward 16 hours after arrival]

    Postoperative pain during rest and movement measured by numeric rating scale (NRS).

  11. Postoperative pain at maternity ward 20 hours after arrival [At maternity ward 20 hours after arrival]

    Postoperative pain during rest and movement measured by numeric rating scale (NRS).

Secondary Outcome Measures

  1. Postoperative nausea and vomiting at postoperative care unit [During stay at postoperative care unit, estimated average 2 hours]

    Present (yes/no) during stay at the postoperative care unit

  2. Postoperative nausea and vomiting at maternity ward [During stay at maternity ward, estimated average 22 hours]

    Present (yes/no) during stay at the maternity ward

  3. Postoperative pruritus at postoperative care unit [During stay at postoperative care unit, estimated average 2 hours]

    Present (yes/no) during stay at the postoperative care unit

  4. Postoperative pruritus at maternity ward [During stay at maternity ward, estimated average 22 hours]

    Present (yes/no) during stay at the maternity ward

  5. Postoperative additional oxycodone consumption at postoperative care unit [During stay at postoperative care unit, estimated average 2 hours]

    Number of mg of oxycodone administered as additional analgetics

  6. Postoperative additional oxycodone consumption at maternity ward [During stay at maternity ward, estimated average 22 hours]

    Number of mg of oxycodone administered as additional analgetics

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Healthy parturient, term pregnancy, undergoing caesarian section
Exclusion Criteria:
  • Patient refusal

  • Maternal heart or lung disease (not including mild asthma)

  • Known or suspected obstructive sleep apnoea syndrome

  • Pre-eclampsia

  • Body mass index > 40

  • Indulin-dependent diabetes mellitus

  • Contraindications to ibuprofen, dexamethasone or morphine

  • Chronic pain

  • Neurological disease

  • Drug abuse

  • Age < 18 years

  • American Society of Anesthesiologists (ASA) 3

  • Patients receiving other forms of anaesthesia (epidural or general)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Stavanger University Hospital Stavanger Rogaland Norway 4068

Sponsors and Collaborators

  • Conrad Arnfinn Bjørshol

Investigators

  • Study Chair: Conrad A Bjørshol, PhD, MD, Helse Stavanger HF

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Conrad Arnfinn Bjørshol, Senior researcher, Helse Stavanger HF
ClinicalTrials.gov Identifier:
NCT05659823
Other Study ID Numbers:
  • 1399-2435
First Posted:
Dec 21, 2022
Last Update Posted:
Dec 21, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 21, 2022